Literature DB >> 20346528

HPV and high-risk gene expression profiles predict response to chemoradiotherapy in head and neck cancer, independent of clinical factors.

Monique C de Jong1, Jimmy Pramana, Joost L Knegjens, Alfons J M Balm, Michiel W M van den Brekel, Michael Hauptmann, Adrian C Begg, Coen R N Rasch.   

Abstract

PURPOSE: The purpose of this study was to combine gene expression profiles and clinical factors to provide a better prediction model of local control after chemoradiotherapy for advanced head and neck cancer.
MATERIAL AND METHODS: Gene expression data were available for a series of 92 advanced stage head and neck cancer patients treated with primary chemoradiotherapy. The effect of the Chung high-risk and Slebos HPV expression profiles on local control was analyzed in a model with age at diagnosis, gender, tumor site, tumor volume, T-stage and N-stage and HPV profile status.
RESULTS: Among 75 patients included in the study, the only factors significantly predicting local control were tumor site (oral cavity vs. Pharynx, hazard ratio 4.2 [95% CI 1.4-12.5]), Chung gene expression status (high vs. Low risk profile, hazard ratio 4.4 [95% CI 1.5-13.3]) and HPV profile (negative vs. Positive profile, hazard ratio 6.2 [95% CI 1.7-22.5]).
CONCLUSIONS: Chung high-risk expression profile and a negative HPV expression profile were significantly associated with increased risk of local recurrence after chemoradiotherapy in advanced pharynx and oral cavity tumors, independent of clinical factors. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20346528     DOI: 10.1016/j.radonc.2010.02.001

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  12 in total

Review 1.  Gene Expression Signatures for Head and Neck Cancer Patient Stratification: Are Results Ready for Clinical Application?

Authors:  Luca Tonella; Marco Giannoccaro; Salvatore Alfieri; Silvana Canevari; Loris De Cecco
Journal:  Curr Treat Options Oncol       Date:  2017-05

Review 2.  Counseling the patient with potentially HPV-related newly diagnosed head and neck cancer.

Authors:  John P Finnigan; Andrew G Sikora
Journal:  Curr Oncol Rep       Date:  2014-03       Impact factor: 5.075

3.  Tumor Cell Extrinsic Synaptogyrin 3 Expression as a Diagnostic and Prognostic Biomarker in Head and Neck Cancer.

Authors:  Ryan M Murphy; Jason Tasoulas; Alessandro Porrello; Miranda B Carper; Yi-Hsuan Tsai; Alisha R Coffey; Sunil Kumar; Peter Yf Zeng; Travis P Schrank; Bentley R Midkiff; Stephanie Cohen; Ashley H Salazar; Michele C Hayward; D Neil Hayes; Andrew Olshan; Gaorav P Gupta; Anthony C Nichols; Wendell G Yarbrough; Chad V Pecot; Antonio L Amelio
Journal:  Cancer Res Commun       Date:  2022-09-15

4.  Intranodal cystic changes: a potential radiologic signature/biomarker to assess the human papillomavirus status of cases with oropharyngeal malignancies.

Authors:  Ajaykumar C Morani; Avraham Eisbruch; Thomas E Carey; Samantha J Hauff; Heather M Walline; Suresh K Mukherji
Journal:  J Comput Assist Tomogr       Date:  2013 May-Jun       Impact factor: 1.826

5.  Potentially novel candidate biomarkers for head and neck squamous cell carcinoma identified using an integrated cell line-based discovery strategy.

Authors:  Lusia Sepiashvili; Angela Hui; Vladimir Ignatchenko; Willa Shi; Susie Su; Wei Xu; Shao Hui Huang; Brian O'Sullivan; John Waldron; Jonathan C Irish; Bayardo Perez-Ordonez; Fei-Fei Liu; Thomas Kislinger
Journal:  Mol Cell Proteomics       Date:  2012-08-23       Impact factor: 5.911

6.  Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer.

Authors:  Jolien Heukelom; Olga Hamming; Harry Bartelink; Frank Hoebers; Jordi Giralt; Teresa Herlestam; Marcel Verheij; Michiel van den Brekel; Wouter Vogel; Nick Slevin; Eric Deutsch; Jan-Jakob Sonke; Philippe Lambin; Coen Rasch
Journal:  BMC Cancer       Date:  2013-02-22       Impact factor: 4.430

7.  Phase I trial of oral etoposide in combination with radiotherapy in head and neck squamous cell carcinoma - GORTEC 2004-02.

Authors:  Yungan Tao; Etienne Bardet; Dominique Rosine; Frédéric Rolland; Emmanuelle Bompas; Nicolas Daly-Schveitzer; Antoine Lusinchi; Jean Bourhis
Journal:  Radiat Oncol       Date:  2013-02-27       Impact factor: 3.481

8.  Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients.

Authors:  Géraldine Descamps; Yasemin Karaca; Jérôme R Lechien; Nadège Kindt; Christine Decaestecker; Myriam Remmelink; Denis Larsimont; Guy Andry; Samantha Hassid; Alexandra Rodriguez; Mohammad Khalife; Fabrice Journe; Sven Saussez
Journal:  J Cancer Res Clin Oncol       Date:  2016-07-01       Impact factor: 4.553

9.  Definitive treatment of primary vaginal cancer with radiotherapy: multi-institutional retrospective study of the Korean Radiation Oncology Group (KROG 12-09).

Authors:  Ji Hyun Chang; Won Il Jang; Yong Bae Kim; Jin Hee Kim; Young Seok Kim; Yeon Sil Kim; Won Park; Juree Kim; Won Sup Yoon; Joo-Young Kim; Hak Jae Kim
Journal:  J Gynecol Oncol       Date:  2016-03       Impact factor: 4.401

10.  Non-coding RNAs profiling in head and neck cancers.

Authors:  Daria Salyakina; Nicholas F Tsinoremas
Journal:  NPJ Genom Med       Date:  2016-01-13       Impact factor: 8.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.